Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
Saved in:
| Title: | Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial. |
|---|---|
| Authors: | Pu T; Digestive Oncology, KU Leuven, Belgium., Peddle AM; Digestive Oncology, KU Leuven, Belgium., Wirapati P; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Tsantoulis P; Geneva University Hospitals, Geneva, Switzerland., Wu Q; Digestive Oncology, KU Leuven, Belgium., Hong Y; Digestive Oncology, KU Leuven, Belgium., Samuel L; Oncology Department, School of Medicine, Medical Sciences and Nutrition, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, UK., Desai J; Peter MacCallum Cancer Centre, Melbourne, Australia., Riener M; Docrates Syöpäsairaala, Helsinki, Finland., Saridaki Z; First Oncology Department, Metropolitan Hospital, Piraeus, Greece.; Asklepios, Oncology Department, Heraklion, Greece., Cunningham D; The Royal Marsden Hospital, London, UK., Tejpar S; Digestive Oncology, KU Leuven, Belgium. sabine.tejpar@uzleuven.be. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2026 Jan 13; Vol. 10 (1), pp. 50. Date of Electronic Publication: 2026 Jan 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
